Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020

By sjmartinez • October 28, 2022

Qian MF, Betancourt NJ, Pineda A, Maloney NJ, Nguyen KA, Reddy SA, Hall ET, Swetter SM, Zaba LC. Health Care Utilization and Costs in Systemic Therapies for Metastatic Melanoma from 2016 to 2020. Oncologist. 2022 Oct 27:oyac219. doi: 10.1093/oncolo/oyac219. Epub ahead of print. PMID: 36302223.

Tags: administrative claims, Dermatology, healthcare, Healthcare cost, immune checkpoint inhibitors, melanoma, molecular targeted therapy, Publications

52-Week Safety and Disease Control With Ruxolitinib Cream in Children Aged 2 to 11 Years With Atopic Dermatitis: Results From the Phase 3 TRuE-AD3 Study

Paller AS, Stein Gold LF, Simpson EL, Zaenglein AL, Armstrong AW, Tollefson MM, Soong W, Lee LW, Devani AR, Forman SB, Siri DD, Kallender H,[...]

Consistency of skin clearance with icotrokinra across patient subgroups with plaque psoriasis

Gold LS, Armstrong AW, Vender RB, Soung J, Pink AE, Cafone J, Edem BE, Reyes-Servin O, Jiang J, Cresswell K, DeKlotz CMC, Miller-Kassamali M, Yang[...]

Real-World Patient and Disease Characteristics, Treatment Outcomes and Satisfaction in Psoriasis: A Cross-Sectional and Retrospective Comparison of Advanced Therapies and Severities

Stein Gold L, Sofen HL, Siu K, Syeed S, Edson-Heredia E, Mitchell B, Goddard E, Kranz B, Gillespie-Akar L, Armstrong AW. Real-World Patient and Disease[...]